Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages

Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages

Objective: The combination of epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) leads to an increased incidence of severe immune-related adverse events (irAEs). However, the mechanisms underlying macrophages in irAEs have not been elucid...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuan Li, Yanping Chen, Yuan Meng, Meng Shen, Fan Yang, Xiubao Ren
Format: Article
Language:English
Published: China Anti-Cancer Association 2024-12-01
Series:Cancer Biology & Medicine
Subjects:
osimertinib
icis
iraes
macrophages
il-6/jak/stat3
Online Access:https://www.cancerbiomed.org/content/21/12/1156
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items